Recent rhetoric in the media and from the United States Federal Government has called into question the effectiveness of antidepressants, namely selective serotonin reuptake inhibitors (SSRIs), among other psychiatric pharmacotherapies. Selective serotonin reuptake inhibitors have also been mentioned as potentially addictive similar to illicit narcotics and a potential threat to patients despite their status as first-line medications in treating depression. The purpose of this commentary is to review the potentially damaging effects such actions and language could have on patient perceptions of their conditions and medications, adherence, and in patients seeking mental healthcare secondary to the reinforcement of damaging stigma.
LeeBWangYCarlsonSA, et al. National, state—level, and county—level prevalence estimates of adults aged ≥18 years self—reporting a lifetime diagnosis of depression—United States, 2020. MMWR Morb Mortal Wkly Rep. 2023;72(24):644-650. doi:10.15585/mmwr.mm7224a1.
2.
BrodyDGuQ.Antidepressant use among adults: United States, 2015–2018. NCHS Data Brief. Hyattsville, MD: National Center for Health Statistics; 2020:1-8.
3.
ElmarasiMFuehrleinB.US medicaid program: an analysis of the spending and utilization patterns for antidepressants from 2017 to 2021. Explor Res Clin Soc Pharm. 2023;13:100392. doi:10.1016/j.rcsop.2023.100392.
NuttDJGoodwinGMBhugraDFazelSLawrieS.Attacks on antidepressants: signs of deep-seated stigma?Lancet Psychiatry. 2014;1(2):102-104. doi:10.1016/S2215-0366(14)70232-9.
6.
ThornicroftGSunkelCMilenovaM; Commission Imple-mentation Partnership. How to stop stigma: implementing The Lancet commission on ending stigma and discrimination in mental health. Lancet Psychiatry. 2024;11(2):88-89. doi:10.1016/S2215-0366(23)00374-7.
DemainSGonçalvesACAreiaC, et al. Living with, managing and minimising treatment burden in long term conditions: a systematic review of qualitative research. PLoS ONE. 2015;10(5):e0125457. doi:10.1371/journal.pone.0125457.
9.
StuartH.Media portrayal of mental illness and its treatments: what effect does it have on people with mental illness?CNS Drugs. 2006;20(2):99-106. doi:10.2165/00023210-200620020-00002.
10.
PathakALimELawrieS.Needlessly controversial: the reporting of pharmaco- and psycho-therapy for the treatment of depression in the UK media. Psychol Med. 2021;51(16):2798-2803. doi:10.1017/S0033291720001427.
11.
GreenLauridsen MKälvemarkSporrong S. How does media coverage effect the consumption of antidepressants? a study of the media coverage of antidepressants in Danish online newspapers 2010-2011. Res Social Adm Pharm. 2018;14(7):638-644. doi:10.1016/j.sapharm.2017.07.011.
12.
HijaziBPopoviciINusairM, et al. Patterns and factors associated with SSRI medication adherence: a retrospective study using pharmacy claims data. J Pharm Health Serv. 2023;14(4):392-400. doi.org/10.1093/jphsr/rmad041.
13.
ShiJChenYJiangY, et al. Stigma and its associations with medication adherence in major depressive disorder. Psychiatry Res. 2024;331:115664. doi:10.1016/j.psychres.2023.115664.
14.
SrimongkonPAslaniPChenTF.Consumer-related factors influencing antidepressant adherence in unipolar depression: a qualitative study. Patient Prefer Adherence. 2018;12:1863-1873. doi:10.2147/PPA.S160728.
15.
YokoyaSMaenoTSakamotoNGotoRMaenoT.A brief survey of public knowledge and stigma towards depression. J Clin Med Res. 2018;10(3):202-209. doi:10.14740/jocmr3282w.
16.
CroweMInderMMcCallC.Experience of antidepressant use and discontinuation: a qualitative synthesis of the evidence. J Psychiatr Ment Health Nurs. 2023;30(1):21-34. doi:10.1111/jpm.12850.
17.
RidgeDKokanovicRBroomAKirkpatrickSAndersonCTannerC.“My dirty little habit”: patient constructions of antidepressant use and the “crisis” of legitimacy. Soc Sci Med. 2015;146:53-61. doi:10.1016/j.socscimed.2015.10.012.
18.
HoSCJacobSATangiisuranB.Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: a qualitative study. PLoS ONE. 2017;12(6):e0179290. doi:10.1371/journal.pone.0179290.
19.
FredericksenRJGibbonsLBrownS, et al. Medication understanding among patients living with multiple chronic conditions: implications for patient-reported measures of adherence. Res Social Adm Pharm. 2018;14(6):540-544. doi: 10.1016/j.sapharm.2017.06.009.
20.
Field-SpringerKStrileyKByerlyJSimmonsNFerrellTQuigleyS.‘Are you vaccinated? yeah, I’m immunized’: a risk orders theory analysis of celebrity COVID-19 misinformation. J Commun Healthc. 2024;17(4):317-327. doi: 10.1080/17538068.2024.2320984.
21.
HorneRWeinmanJ.Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-567. doi:10.1016/s0022-3999(99)00057-4.
22.
RafhiEAl-JuhaishiMStupansIStevensJEParkJSWangKN.The influence of patients’ beliefs about medicines and the relationship with suboptimal medicine use in community-dwelling older adults: a systematic review of quantitative studies. Int J Clin Pharm. 2024;46(4):811-830. doi:10.1007/s11096-024-01727-9.
23.
WestLMBorgTheuma RCordinaM.The “necessity-concerns framework” as a means of understanding non-adherence by applying polynomial regression in three chronic conditions. Chronic Illn. 2020;16(4):253-265. doi:10.1177/1742395318799847.
24.
ReadJCartwrightCGibsonKShielsCHaslamN.Beliefs of people taking antidepressants about causes of depression and reasons for increased prescribing rates. J Affect Disord. 2014;168:236-242. doi:10.1016/j.jad.2014.06.010.
25.
O’BrienC.Addiction and dependence in DSM-V. Addiction. 2011;106(5):866-867. doi:10.1111/j.1360-0443.2010.03144.x.
26.
American Academy of Pain Medicine the American Pain Society the American Society of Addition Medicine. Definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100(5):28-29.
27.
HorowitzMAFramerAHengartnerMPSørensenATaylorD.Estimating risk of antidepressant withdrawal from a review of published data. CNS Drugs. 2023;37(2):143-157. doi:10.1007/s40263-022-00960-y.
DaviesJReadJ.A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based?Addict Behav. 2019;97:111-121. doi:10.1016/j.Addbeh.2018.08.027.
30.
VirtanenSLagerbergTKhemiriL, et al. Association of selective serotonin re-uptake inhibitor (SSRI) treatment with acute substance misuse outcomes. Addiction. 2022;117(1):234-242. doi:10.1111/add.15625.
31.
KuykenWHayesRBarrettB, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence (PREVENT): a randomized controlled trial. Lancet. 2015;386(9988):63-73. doi:10.1016/S0140-6736(14)62222-4.
32.
LamRWKennedySHAdamsC, et al. Canadian network for mood and anxiety treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Can J Psychiatry. 2024;69(9):641-687. doi:10.1177/07067437241245384.
33.
AlemiFMinHYousefiM, et al. Effectiveness of common antidepressants: a post market release study. Eclinicalmedicine. 2021;41:101171. doi:10.1016/j.eclinm.2021.101171.
34.
MurphySECapitãoLPGilesSLCCowenPJStringarisAHarmerCJ.The knowns and unknowns of SSRI treatment in young people with depression and anxiety: efficacy, predictors, and mechanisms of action. Lancet Psychiatry. 2021;8(9):824-835. doi:10.1016/S2215-0366(21)00154-1.
35.
DragiotiESolmiMFavaroA, et al. Association of antidepressant use with adverse health outcomes: a systematic umbrella review [published correction appears in JAMA Psychiatry. 2021;78(5):569. doi: 10.1001/jamapsychiatry.2021.0314.]. JAMA Psychiatry. 2019;76(12):1241-1255. doi:10.1001/jamapsychiatry.2019.2859.
36.
BuschSHFrankRGLeslieDL, et al. Antidepressants and suicide risk: how did specific information in FDA safety warnings affect treatment patterns?Psychiatr Serv. 2010;61(1):11-16. doi:10.1176/appi.ps.61.1.11.
37.
HallRCWFriedmanSHSorrentinoRLapchenkoMMarcusAEllisR. The myth of school shooters and psychotropic medications. Behav Sci Law. 2019;37(5):540-558. doi:10.1002/bsl.2429.
38.
HengartnerMP.Methodological flaws, conflicts of interest, and scientific fallacies: implications for the evaluation of antidepressants’ efficacy and harm. Front Psychiatry. 2017;8:275. doi:10.3389/fpsyt.2017.00275.
39.
AndrewsPWThomsonJAJrJrAmstadterANealeMC.Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front Psychol. 2012;3:117. doi:10.3389/fpsyg.2012.00117.
